title: [Epidemiological and therapeutic study on urethritis of male and cervicitis from viewpoint of STD--a study using NY-198. Sapporo Clinical Research Group for STD].
abstract: Urethritis in males and cervicitis in females, which were sexually transmitted diseases, were treated with NY-198, a new quinolone antibiotic, and its efficacy was studied. Seventeen male patients with gonorrheal urethritis were administered a single 300 mg dose of NY-198. The efficacy rate on the 3rd day after administration was 100%, but it was 85.7% on the 7th day due to recurrence in 1 patient. The results of treatment of non-gonorrheal infections were as follow. In this treatment, NY-198 was administered in a daily dose of 600 mg in 3 divided doses for 14 consecutive days. In the treatment of chlamydial urethritis of males, the efficacy rate in 26 patients was 84.6% on the 7th day and 84.0% on the 14th day in 25 patients. In the treatment of chlamydial cervicitis, the efficacy rate was 100% on both the 7th (3/3) and 14th (6/6) days. In the treatment of non-gonorrheal and non-chlamydial cervicitis, the efficacy rate was 100% on the 7th day (1/1) and 50% (1/2) on 14th day. The efficacy rate in all 40 males with non-gonorrheal urethritis was 85.0% on the 7th day and 88.9% for 36 patients on the 14th day, while that in all 4 females with cervicitis was 100% on the 7th day and 87.5% on the 14th day. No side effects were seen in any of the patients. Overall, NY-198 had an efficacy rate of 80% in the treatment of chlamydial infections. NY-198 was found to be a useful drug which is efficacious in the treatment of all STD-related microbes such as gonococci and chlamydia.
authors.affiliation: Department of Urology, Sapporo Medical College.
authors.forename: Y
authors.initials: Y
authors.lastname: Kumamoto
authors.forename: T
authors.initials: T
authors.lastname: Miyagishi
authors.forename: T
authors.initials: T
authors.lastname: Hirose
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: T
authors.initials: T
authors.lastname: Gohro
authors.forename: T
authors.initials: T
authors.lastname: Ueno
authors.forename: K
authors.initials: K
authors.lastname: Mohri
authors.forename: N
authors.initials: N
authors.lastname: Kodama
authors.forename: K
authors.initials: K
authors.lastname: Abe
mesh_terms: D042462:4-Quinolones; D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002690:Chlamydia Infections; D002692:Chlamydia trachomatis / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D005260:Female; D024841:Fluoroquinolones; D006069:Gonorrhea; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects*; D015363:Quinolones; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000453:epidemiology*; D014526:Urethritis / Q000188:drug therapy / Q000453:epidemiology*; D002575:Uterine Cervicitis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin